Meet our team and learn how Haystack MRD advances ctDNA detection for breast cancer care
Haystack MRD® by Quest Diagnostics® will be at the San Antonio Breast Cancer Symposium® (SABCS), taking place December 9 to 12 in San Antonio, Texas. Visit us at Quest Diagnostics booth 1426 to explore how our tumor-informed minimal residual disease (MRD) test delivers precise, clinically meaningful insights using advanced circulating tumor DNA (ctDNA) detection technology.
Haystack MRD is designed to support confident treatment decisions by providing highly accurate molecular insights into disease status. Stop by the booth to speak with our clinical and scientific team, review case examples, and learn how Haystack MRD integrates into your workflow.
Why meet with us at SABCS?
Haystack MRD offers
- An exceptionally accurate, tumor-informed assay built to detect ultralow levels of ctDNA
- Patented error-correction technology that double-checks each variant to distinguish true signal from noise
- A streamlined testing experience powered by Quest Diagnostics
- Confident insights to support therapeutic decisions in the neoadjuvant, adjuvant, therapy response, and surveillance settings
- Support for clinical trials through patient enrichment, stratification, and response monitoring
Whether you are evaluating MRD strategies for your institution or want to deepen your understanding of ctDNA detection in breast cancer care, we welcome the opportunity to speak with you.
Visit us at Quest Diagnostics booth #1426
- Exhibit hall is open December 10-12
- San Antonio, Texas
- Conference details: https://sabcs.org/
If you would like to set up time with our team during SABCS, please contact us here:
